{Reference Type}: Case Reports
{Title}: Durable Response in Relapsed Adolescent Peripheral T-cell Lymphoma: A Case Report and Review of the Literature.
{Author}: Wedekind MF;Saraf A;Willen F;Audino AN;
{Journal}: J Pediatr Hematol Oncol
{Volume}: 44
{Issue}: 1
{Year}: 01 2022 1
{Factor}: 1.17
{DOI}: 10.1097/MPH.0000000000002147
{Abstract}: Peripheral T-cell lymphoma (PTCL) is an aggressive tumor, rarely seen in pediatrics or adolescent and young adults (AYAs) so there is no upfront or relapsed standard of care. The authors describe a 16-year-old with PTCL, treated with chemotherapy and autologous stem cell transplant. Upon relapse, he received ifosfamide, carboplatin, etoposide, and radiation with durable remission of 4 years. Data in pediatric/AYA PCTL continue to lack an understanding of the biology and microenvironment, the differences to adult patients, and a lack of adequate therapy. Targeted therapy may improve outcomes for children and AYAs with refractory or relapsed PTCL.